Harbour Capital Advisors LLC Sells 84 Shares of Zoetis Inc. (NYSE:ZTS)

Harbour Capital Advisors LLC trimmed its position in Zoetis Inc. (NYSE:ZTS) by 1.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,483 shares of the company’s stock after selling 84 shares during the quarter. Harbour Capital Advisors LLC’s holdings in Zoetis were worth $1,059,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Mizuho Securities USA LLC raised its position in shares of Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after buying an additional 4,829,815 shares in the last quarter. International Assets Investment Management LLC increased its stake in Zoetis by 41,235.7% during the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after acquiring an additional 937,700 shares during the last quarter. Marshall Wace LLP raised its position in Zoetis by 7,608.6% during the second quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock valued at $144,874,000 after purchasing an additional 824,843 shares during the period. Nordea Investment Management AB lifted its stake in shares of Zoetis by 38.3% in the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock valued at $336,266,000 after purchasing an additional 572,511 shares during the last quarter. Finally, Holocene Advisors LP purchased a new position in shares of Zoetis in the 3rd quarter worth approximately $110,809,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 1.8 %

Shares of ZTS stock traded up $2.88 on Monday, hitting $166.20. The stock had a trading volume of 1,191,650 shares, compared to its average volume of 2,331,014. The business has a 50 day moving average price of $171.71 and a 200 day moving average price of $180.29. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The company has a market cap of $74.98 billion, a PE ratio of 31.24, a P/E/G ratio of 2.91 and a beta of 0.89. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.36 earnings per share. Research analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be issued a $0.50 dividend. The ex-dividend date is Tuesday, January 21st. This is an increase from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. Zoetis’s payout ratio is currently 37.59%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ZTS. Leerink Partners started coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. UBS Group initiated coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus decreased their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average target price of $211.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.